Related Experiment Video
Updated: May 4, 2026

Modeling Encephalopathy of Prematurity Using Prenatal Hypoxia-ischemia with Intra-amniotic Lipopolysaccharide in Rats
Published on: November 20, 2015
Portosystemic encephalopathy
1Department of Neurology, Hanover Medical School, Hanover, Germany.
Abstract:
Portosystemic or type C hepatic encephalopathy (HE) is a frequent complication and an indicator of a worsening prognosis in patients with liver cirrhosis. It is characterized by alterations in cognition, consciousness, and motor function. Usually type C HE occurs episodically. However, a few patients also present with chronic progressive symptoms of central nervous system dysfunction. In these cases motor symptoms most often exceed cognitive dysfunction and alterations of consciousness. The most frequent features of these chronic progressive forms of HE are acquired hepatocerebral degeneration and hepatic myelopathy. Current hypotheses about the pathophysiology of type C HE are based on the finding that symptoms occur in the presence of hyperammonemia, especially, but are amplified by accompanying factors such as inflammation, hyponatremia, or the application of benzodiazepines, for example. Accordingly, therapy aims at the reduction of ammonia production and absorption, and, since most of the HE episodes are provoked by nutritional protein overload, gastrointestinal bleeds, infection, medication (especially sedatives or diuretics) or constipation, by treatment of the provoking factor. Of note, this approach does not work in acquired hepatocerebral degeneration and hepatic myelopathy. Here liver transplantation should be considered early in the course of the disease.
Related Concept Videos
Hepatic Encephalopathy
Portal Hypertension
Hepatic Portal System
At its core, the hepatic portal vein is the result of a confluence of the superior and inferior mesenteric veins along with the splenic vein. Each of these veins has a unique role. The superior mesenteric vein is...
Cerebral Edema ll: Pathophysiology
Encephalitis ll: Pathophysiology
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

